{
  "meta": {
    "title": "45_Carcinoma_Cervix",
    "url": "https://brainandscalpel.vercel.app/45-carcinoma-cervix-fc399fc2.html",
    "scrapedAt": "2025-11-30T12:30:07.736Z"
  },
  "questions": [
    {
      "text": "Which serotype of HPV is responsible for carcinoma cervix?",
      "choices": [
        {
          "id": 1,
          "text": "6, 11 31, 32"
        },
        {
          "id": 2,
          "text": "16, 18, 31, 32"
        },
        {
          "id": 3,
          "text": "6, 11, 16, 18"
        },
        {
          "id": 4,
          "text": "16, 18, 31, 33"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>HPV serotypes <strong>16, 18, 31, 33</strong>, 35, 39, 45, 52, 56, 58, 59, 68 are associated with carcinoma cervix.</p>\n<p><strong>Risk factors</strong> for carcinoma cervix include:</p>\n<ul>\n<li>Human Papilloma virus (most important)</li>\n<li>Sexual intercourse before 18 years</li>\n<li>Multiple sexual partners</li>\n<li>Multiparity</li>\n<li>Poor personal hygiene</li>\n<li>Smoking and drug abuse</li>\n<li>Women with STD, HIV, HSV </li>\n<li>Immune suppression</li>\n</ul>\n<p>Polymerase chain reaction (PCR) or southern blot or Hybrid capture technique is used for HPV DNA detection.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4976",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is not true regarding HPV?",
      "choices": [
        {
          "id": 1,
          "text": "E1 and E2 are viral proteins needed for replication"
        },
        {
          "id": 2,
          "text": "E6 and E7 are viral proteins needed for malignant transformation"
        },
        {
          "id": 3,
          "text": "E6 acts via the retinoblastoma gene"
        },
        {
          "id": 4,
          "text": "HPV 16 is the most common serotype causing carcinoma cervix"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>E6</strong> acts via the tumor suppression gene <strong>p53. </strong>It&nbsp;increases proteasome-dependent p53 degradation.&nbsp;<strong>E7</strong> binds and acts via the retinoblastoma (<strong>Rb</strong>) gene.&nbsp;</p>\n<p>The viral <strong>E6 and E7</strong> oncoproteins&nbsp;encoded by the high-risk type HPVs (such as HPV 16 and HPV 18) are necessary for <strong>malignant transformation</strong>.&nbsp;</p>\n<p><strong>E1 and E2</strong>&nbsp;oncoproteins are responsible for viral <strong>replication.</strong></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0991",
      "difficulty": "easy"
    },
    {
      "text": "Which is the HPV serotype most commonly associated with carcinoma cervix?",
      "choices": [
        {
          "id": 1,
          "text": "16"
        },
        {
          "id": 2,
          "text": "18"
        },
        {
          "id": 3,
          "text": "31"
        },
        {
          "id": 4,
          "text": "33"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>HPV 16</strong> is the <strong>most common</strong> type associated with carcinoma cervix.</p>\n<p>Associations between human papilloma virus (HPV) serotypes and carcinoma cervix:</p>\n<ul>\n<li>Most<strong>&nbsp;common</strong>&nbsp;serotype -&nbsp;<strong>HPV 16</strong></li>\n<li>Most<strong>&nbsp;malignant</strong>&nbsp;serotype -&nbsp;<strong>HPV 18</strong></li>\n<li>Most specific serotype - HPV 18</li>\n<li>Most common serotype associated with\n<ul>\n<li>Squamous cell carcinoma - HPV 16</li>\n<li>Adenocarcinoma - HPV 18</li>\n</ul>\n</li>\n</ul>\n<p>Cancers caused by HPV:</p>\n<ul>\n<li>Male - penile, oral, anal</li>\n<li>Female - cervix, vagina, vulva</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4978",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following is false about the Cervarix vaccine?",
      "choices": [
        {
          "id": 1,
          "text": "Protects against HPV types 16 and 18"
        },
        {
          "id": 2,
          "text": "Dose is 0.5ml, intramuscular"
        },
        {
          "id": 3,
          "text": "Protective against genital warts"
        },
        {
          "id": 4,
          "text": "Dosing schedule – 0, 1 and 6 months"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The <strong>Cervarix</strong> vaccine is not protective against genital warts. It is mainly protective against <strong>CIN</strong> and <strong>cervical cancer</strong>.</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Vaccine Type</strong></td>\n<td><strong>Cervarix</strong></td>\n<td><strong>Gardasil</strong></td>\n<td><strong>Gardasil 9</strong></td>\n</tr>\n<tr>\n<td><strong> </strong></td>\n<td>Bivalent vaccine</td>\n<td>Quadrivalent vaccine</td>\n<td>Nonavalent vaccine</td>\n</tr>\n<tr>\n<td>HPV types </td>\n<td>HPV 16,18</td>\n<td>HPV 6, 11, 16, 18</td>\n<td>HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58</td>\n</tr>\n<tr>\n<td>Dosage</td>\n<td>0.5 mL </td>\n<td>0.5 mL</td>\n<td>0.5 mL </td>\n</tr>\n<tr>\n<td>Schedule</td>\n<td>0, 1, 6 months</td>\n<td>0, 2, 6 months</td>\n<td>0, 2, 6 <br />months </td>\n</tr>\n<tr>\n<td>Diseases prevented</td>\n<td>CIN<br /><br />Carcinoma cervix</td>\n<td>CIN<br /><br />Carcinoma cervix<br /><br />Genital warts</td>\n<td>CIN<br /><br />Carcinoma<br />cervix<br /><br />Genital <br />warts<br /><br />Vulval<br />cancer<br /><br />Vaginal<br />epithelial cancer<br /><br />Oropharyngeal<br />cancer</td>\n</tr>\n<tr>\n<td>Adjuvant</td>\n<td>AS04</td>\n<td>Alum</td>\n<td>Alum</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB5010",
      "difficulty": "medium"
    },
    {
      "text": "HPV nonavalent vaccine is active against which of the following serotypes?",
      "choices": [
        {
          "id": 1,
          "text": "6, 11, 16, 18, 20, 23, 35, 42, 52"
        },
        {
          "id": 2,
          "text": "6, 11, 16, 19, 23, 33, 45, 58"
        },
        {
          "id": 3,
          "text": "6, 11, 16, 18, 32, 34, 45, 52, 58"
        },
        {
          "id": 4,
          "text": "6, 11, 16, 18, 31, 33, 45, 52, 58"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>HPV <strong>nonavalent</strong> vaccine (<strong>Gardasil 9 or HPV9</strong>) is active against <strong>HPV 6,11,16,18,31,33,45,52,58.</strong></p>\n<p>Currently, HPV nonnavalent vaccine has replaced <strong>Gardasil</strong> which is a <strong>quadrivalent</strong> vaccine acting against <strong>6,11,16,18.</strong></p>\n<p>Vaccines available for HPV:&nbsp;</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Brand name</strong></td>\n<td><strong>Cervarix</strong></td>\n<td><strong>Gardasil</strong></td>\n<td><strong>Gardasil-9</strong></td>\n<td>&nbsp;<strong data-stringify-type=\"bold\">Cervavac</strong></td>\n</tr>\n<tr>\n<td>Characteristic and HPV subtypes</td>\n<td>Bivalent:<strong>16,18</strong></td>\n<td>Quadrivalent: <strong>6,11,16,18</strong></td>\n<td>Nonavalent: <strong>6,11,16,18,31,33,45,52,58</strong></td>\n<td>&nbsp;Quadrivalent: <strong>6,11,16,18</strong></td>\n</tr>\n<tr>\n<td>Protects against:</td>\n<td>\n<ul>\n<li>CIN</li>\n<li>CA cervix</li>\n</ul>\n</td>\n<td>\n<ul>\n<li><strong>Anogenital warts</strong></li>\n<li>CIN</li>\n<li>CA cervix</li>\n</ul>\n</td>\n<td>\n<ul>\n<li>Anogenital warts</li>\n<li>CIN</li>\n<li>CA cervix &nbsp;</li>\n<li><strong>Vulval </strong>intraepithelial<strong> neoplasia</strong></li>\n<li><strong>Vaginal </strong>intraepithelial<strong> neoplasia</strong></li>\n<li><strong>Anal cancer</strong></li>\n<li><strong>Oropharyngeal cancer</strong></li>\n<li><strong>Head and neck cancers</strong></li>\n</ul>\n</td>\n<td>\n<ul>\n<li><strong>Anogenital warts</strong></li>\n<li>CIN</li>\n<li>CA cervix</li>\n</ul>\n&nbsp;</td>\n</tr>\n<tr>\n<td>Dose</td>\n<td><strong>0.5 ml</strong>, <strong>IM</strong>.</td>\n<td><strong>0.5 ml</strong>, <strong>IM</strong>.</td>\n<td><strong>0.5 ml</strong>, <strong>IM</strong>.</td>\n<td>&nbsp;<strong>0.5 ml</strong>, <strong>IM</strong>.</td>\n</tr>\n<tr>\n<td>Ideal Age range:</td>\n<td>\n<p>Ideally at 11-12 years or</p>\n<p>9-26 years&nbsp;</p>\n</td>\n<td>\n<p>Ideally at 11-12 years or</p>\n<p>9-26 years&nbsp;</p>\n</td>\n<td>\n<p>Ideally at 11-12 years or</p>\n<p>9-26 years&nbsp;</p>\n</td>\n<td>\n<p>The targeted age group is 9-26 years</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p><div class=\"row mt-3\">As per the&nbsp;<strong data-stringify-type=\"bold\">December 2022 WHO&nbsp;</strong>updated dose schedules on<strong data-stringify-type=\"bold\">&nbsp;HPV vaccines,</strong>&nbsp;the recommendations for different age groups are as follows:</div>\n<div class=\"row mt-3\">\n<div class=\"row mt-3\">\n<ul>\n<li><strong>1 or 2 doses</strong>&nbsp;scheduled<strong>&nbsp;</strong>for the primary target of girls aged&nbsp;<strong>9&ndash;14 years</strong>.</li>\n<li><strong>1 or 2 doses</strong>&nbsp;scheduled&nbsp;for young women aged&nbsp;<strong>15&ndash;20 years</strong>.</li>\n<li><strong>2</strong>&nbsp;doses with a&nbsp;<strong>6-month interval</strong>&nbsp;for women&nbsp;<strong>older than 21 years</strong>.</li>\n<li>\n<div class=\"p-rich_text_section\">A minimum of<strong data-stringify-type=\"bold\">&nbsp;2 doses</strong>&nbsp;and when feasible <strong>3 doses</strong>&nbsp;remain necessary for those known to be<strong data-stringify-type=\"bold\">&nbsp;immunocompromised </strong>and/or<strong data-stringify-type=\"bold\"> HIV-infected</strong>.</div>\n</li>\n</ul>\n</div>\n</div><hr><h3>Related Pearl: Human Papilloma Virus (HPV) and Associated Lesions</h3><table>\n<tbody>\n<tr>\n<td><strong>HPV serotype</strong></td>\n<td><strong>Lesions</strong></td>\n</tr>\n<tr>\n<td>HPV 1,2,3,4</td>\n<td>\n<div class=\"page\" title=\"Page 566\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<ul>\n<li>Common warts (verruca vulgaris, plantar wart)</li>\n</ul>\n</div>\n</div>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td>HPV 6 and 11</td>\n<td>\n<ul>\n<li>Condyloma acuminatum (genital warts)</li>\n<li>Sinonasal papilloma</li>\n<li>Squamous papilloma of the larynx</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>HPV 16</td>\n<td>\n<ul>\n<li>LSIL, HSIL, carcinoma cervix</li>\n<li>Vulval carcinoma</li>\n<li>Bowen disease (Carcinoma in situ of male external genitalia)</li>\n<li>Oropharyngeal squamous cell carcinoma</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>HPV 18</td>\n<td>\n<ul>\n<li>LSIL, HSIL, Carcinoma of the cervix</li>\n<li>Carcinoma of the anogenital region</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>HPV 5 and 8</td>\n<td>\n<ul>\n<li>Squamous cell carcinoma of the skin in epidermodysplasia verruciformis patients</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>\n<p>LSIL: Low-grade squamous intraepithelial lesion</p>\n<p>HSIL: High-grade squamous intraepithelial lesion&nbsp;&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB9222",
      "difficulty": "easy"
    },
    {
      "text": "A 45-year-old patient comes with repeated infections of trichomonas vaginitis, her physician advises for a Pap smear. She asks you regarding the purpose of this test. What would be your appropriate response?",
      "choices": [
        {
          "id": 1,
          "text": "It is a screening test for cervical cancer"
        },
        {
          "id": 2,
          "text": "It is a diagnostic test for trichomonas infection"
        },
        {
          "id": 3,
          "text": "It helps to diagnose cancer in her genital tract"
        },
        {
          "id": 4,
          "text": "It helps to diagnose other associated genital infections in her"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>A pap smear is a <strong>screening test</strong> for cervical <strong>cancer</strong>. It is not a diagnostic test (option C). The presence of abnormal cells/ a positive test requires further evaluation by colposcopy, cervical biopsy, or fractional curettage.&nbsp;</p>\n<p>If trichomonas is reported from Pap testing, it should be confirmed by saline microscopic preparation (option B).&nbsp;</p>\n<p>Cervical cancer<strong> screening</strong> should start at <strong>age 21</strong>. Women aged<strong> 21-29</strong> should have a<strong> Pap smear every 3 years</strong>, while women aged<strong> 30-65</strong> should have both <strong>HPV and Pap co-test</strong> every <strong>5 years</strong>.&nbsp;Women should stop having cervical cancer screening after the age of <strong>65 years</strong>. If suspicious PAP, screening till 75 years. HIV+ women should have annual checkups until three consecutive negative tests followed by testing every 3 years for life.</p>\n<p>Pap testing should be done <strong>prior</strong> to <strong>vaginal examination.&nbsp;</strong>Lubricants should not be used and the&nbsp;patient should not be menstruating during the pap test. The patient should not have intercourse 24hrs prior to the test. The ideal <strong>time</strong> is around <strong>ovulation</strong>.&nbsp;</p>\n<p><strong>Procedure</strong>:</p>\n<ul>\n<li>The patient is put in a <strong>dorsal</strong> position, and the labia are parted</li>\n<li><strong>Cusco&rsquo;s</strong> self-retaining <strong>speculum</strong> is introduced</li>\n<li>The <strong>squamocolumnar junction</strong> is scraped with <strong>Ayer&rsquo;s</strong> <strong>spatula</strong>:\n<ul>\n<li>Bifid end - ectocervical sample</li>\n<li>Blunt end - vaginal cytology</li>\n</ul>\n</li>\n<li><strong>Endocervix</strong> is scraped with a <strong>cytobrush</strong></li>\n<li>The sample is spread on <strong>a</strong> <strong>glass slide</strong></li>\n<li>The slide is immediately fixed using <strong>95%</strong> <strong>ethyl</strong> <strong>alcohol</strong></li>\n<li>Stained with Papanicolau stain or short-duration<strong>&nbsp;</strong>Papanicolau stain (SPS).</li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/af717526ba7c45ce810e6bbe8f7409bex1280x4631.JPEG\" alt=\"Explanation Image\"><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/61db0cacf41240c59c87765886aff277x1280x2262.JPEG\" alt=\"Explanation Image\"><hr><h3>Related Pearl: Management of CIN</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/1f5d51f1183f4d35857dd881e7f7f708x1280x1886.JPEG\" alt=\"Pearl Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD6623",
      "difficulty": "easy"
    },
    {
      "text": "A 24-year-old woman comes to the gynecology OPD for a routine Pap smear. The histopathology slide is shown below. Identify the cell marked as \"A\".",
      "choices": [
        {
          "id": 1,
          "text": "Superficial cell"
        },
        {
          "id": 2,
          "text": "Basal cell"
        },
        {
          "id": 3,
          "text": "Parabasal cell"
        },
        {
          "id": 4,
          "text": "Intermediate cell"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The cell marked A is the <strong>superficial cell. </strong></p>\n<p>ACOG guidelines recommend cervical exfoliative cytology every 3 years starting 21 years as screening for cervical cancer.</p>\n<p>The image below shows a <strong>superficial cell</strong> (a) and an <strong>intermediate cell</strong> (b):</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/1feb770911f24d8a9a92b99b27b10988x504x273.JPEG\" alt=\"Explanation Image\"><p><br />The image below shows <strong>parabasal cells</strong> (marked by black arrows):</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/75f4419b83944bfca4ed48d10a6b0594x800x533.JPEG\" alt=\"Explanation Image\"><p> </p>\n<p><strong>Koilocytes</strong> are epithelial cells that contain eccentric, hyperchromatic, moderately <strong>enlarged nucleus</strong> that is displaced by large <strong>perinuclear vacuole</strong>. It is a feature of <strong>HPV infection</strong>.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/aad3c0e4647d47399d6f0a31bc833497x720x537.PNG\" alt=\"Explanation Image\"><hr><h3>Related Pearl: Cytohormonal study of the vaginal epithelium</h3><table>\n<tbody>\n<tr>\n<td><strong>Layer </strong></td>\n<td><strong>Cell characteristics</strong></td>\n<td><strong>Hormones</strong></td>\n<td><strong>Age of the woman</strong></td>\n</tr>\n<tr>\n<td><strong>Parabasal and basal</strong></td>\n<td>Small, round and basophilic with large nuclei</td>\n<td>Lack of hormonal activity</td>\n<td>\n<p><strong>Childhood</strong> until puberty</p>\n<p><strong>Menopause</strong> with atrophy</p>\n</td>\n</tr>\n<tr>\n<td><strong>Intermediate cells</strong></td>\n<td>\n<p>Transparent and basophilic (blue-green) with vesicular nuclei</p>\n</td>\n<td>Progesterone, Androgen, Corticosteroid&nbsp;</td>\n<td>\n<p><strong>Pregnancy</strong></p>\n<p>At an early transition of&nbsp; menopause</p>\n</td>\n</tr>\n<tr>\n<td><strong>Superficial cells</strong></td>\n<td>Large cells with a pyknotic nucleus, acidophilic on staining</td>\n<td>Estrogen</td>\n<td>\n<p><strong>Reproductive period </strong></p>\n<p>Preovulatory phase</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>Note: Malignant cells contain less cytoplasm, and hyperchromatic nuclei which are variable in size.</p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/772c5f242b844d6c8c84c43a83213b77.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0630",
      "difficulty": "medium"
    },
    {
      "text": "Match the following:<div class='question-desc-html'><table>\n<tbody>\n<tr>\n<td>&nbsp;</td>\n<td><strong>Pap classification&nbsp;</strong></td>\n<td>&nbsp;</td>\n<td><strong>Cervical intraepithelial neoplasia grading</strong></td>\n</tr>\n<tr>\n<td>A.</td>\n<td>Grade I</td>\n<td>1.</td>\n<td>Inflammatory</td>\n</tr>\n<tr>\n<td>B.</td>\n<td>Grade II</td>\n<td>2.&nbsp;</td>\n<td>Normal</td>\n</tr>\n<tr>\n<td>C.&nbsp;</td>\n<td>Grade III</td>\n<td>3.</td>\n<td>Squamous cell carcinoma&nbsp;</td>\n</tr>\n<tr>\n<td>D.&nbsp;</td>\n<td>Grade IV</td>\n<td>4.&nbsp;</td>\n<td>CIN I</td>\n</tr>\n<tr>\n<td>E.&nbsp;&nbsp;</td>\n<td>Grade V</td>\n<td>5.&nbsp;</td>\n<td>CIN II, CIN III, CIS</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div></div>",
      "choices": [
        {
          "id": 1,
          "text": "A-2, B-1, C-4, D-5, E-3"
        },
        {
          "id": 2,
          "text": "A-2, B-1, C-4, D-3, E-5"
        },
        {
          "id": 3,
          "text": "A-1, B-2, C-4, D-5, E-3"
        },
        {
          "id": 4,
          "text": "A-2, B-1, C-3, D-5, E-4"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>Various systems of classification are used to describe <strong>cervical cytology after Pap smear</strong> such as:</p>\n<ul>\n<li>Papanicolaou classification - describes the exfoliative cytology of the cervix in a Pap smear.</li>\n<li>Cervical intraepithelial neoplasia (CIN) - histopathological description of how much of the thickness of the cervical epithelium is replaced by dysplastic cells&nbsp;</li>\n<li>Bethesda classification - it is another method to describe cervical dysplasia&nbsp;</li>\n</ul>\n<p>The various systems and their corresponding classes are given below:</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Pap classification (1943)</strong></td>\n<td><strong>Cervical intraepithelial neoplasia / CIN&nbsp; (WHO 1975)</strong></td>\n<td><strong>Bethesda system</strong></td>\n</tr>\n<tr>\n<td>Grade I</td>\n<td>Normal</td>\n<td>Normal</td>\n</tr>\n<tr>\n<td>Grade II</td>\n<td>Inflammatory</td>\n<td>\n<p>Inflammatory</p>\n<p>HPV</p>\n<p>ASCUS</p>\n</td>\n</tr>\n<tr>\n<td>Grade III</td>\n<td>CIN I</td>\n<td>\n<p>Low SIL</p>\n</td>\n</tr>\n<tr>\n<td>Grade IV</td>\n<td>CIN II, CIN III, CIS</td>\n<td>\n<p>High SIL</p>\n</td>\n</tr>\n<tr>\n<td>Grade V</td>\n<td>SCC</td>\n<td>\n<p>SCC</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>where, CIS: Carcinoma in situ, CIN: Cervical intraepithelial neoplasia, SCC: Squamous cell carcinoma, SIL: Squamous intraepithelial lesion, ASCUS: Atypical squamous cell of undetermined significance, HPV: Human papillomavirus.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0639",
      "difficulty": "medium"
    },
    {
      "text": "A 45-year-old lady complains of post-coital bleeding. She has a positive pap smear. What is the next line of management?",
      "choices": [
        {
          "id": 1,
          "text": "Colposcopy directed biopsy"
        },
        {
          "id": 2,
          "text": "Cone biopsy"
        },
        {
          "id": 3,
          "text": "Repeat pap smear"
        },
        {
          "id": 4,
          "text": "Hysterectomy"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The appropriate management of a 45-year-old with a <strong>positive pap</strong> smear and post-coital bleeding is a&nbsp;<strong>colposcopy-directed biopsy.</strong></p>\n<p>A&nbsp;<strong>per speculum examination </strong>must be done whenever a female comes with<strong> post-coital bleeding</strong> in order to evaluate for carcinoma of the cervix. If growth is visible, a punch biopsy should be done, and else if no growth is visible, then a pap smear is done. A pap smear is a <strong>screening test</strong> for cervical <strong>cancer</strong>. The presence of abnormal cells/ a positive test requires further evaluation by <strong>colposcopy,</strong> cervical biopsy, or fractional curettage.</p>\n<p>Cervical cancer<strong> screening</strong> should start at <strong>age 21</strong>. Women aged<strong> 21-29</strong> should have a<strong>&nbsp;pap smear every 3 years</strong>, while women aged<strong> 30-65</strong> should have both <strong>HPV and pap co-test</strong> every <strong>5 years</strong>.&nbsp;Women should stop having cervical cancer screening after the age of <strong>65 years</strong>. If a pap smear is suspicious, then screening is continued till 75 years. HIV+ve women should have annual checkups until three consecutive negative tests followed by testing every 3 years for life.</p>\n<p>Pap testing should be done <strong>prior</strong> to <strong>vaginal examination.&nbsp;</strong>Lubricants should not be used and the&nbsp;patient should not be menstruating during the pap test. The patient should not have intercourse 24hrs prior to the test. The ideal <strong>time</strong> is around <strong>ovulation.</strong></p><hr><h3>Related Pearl: Grades of cervical dysplasia</h3><p>A comparison of various naming systems based on cytology (Bethesda) and biopsy (CIN grade)</p>\n<table>\n<tbody>\n<tr>\n<td><strong>WHO grade</strong></td>\n<td><strong>Bethesda</strong></td>\n<td><strong>CIN grade</strong></td>\n<td><strong>Description</strong></td>\n</tr>\n<tr>\n<td>Mild Dysplasia</td>\n<td>LSIL</td>\n<td>CIN I</td>\n<td>Dysplastic cells in basal 1/3 of cervical epithelium</td>\n</tr>\n<tr>\n<td>Moderate Dysplasia</td>\n<td rowspan=\"3\">HSIL</td>\n<td>CIN II</td>\n<td>Dysplastic cells in basal 2/3 of cervical epithelium</td>\n</tr>\n<tr>\n<td>Severe dysplasia</td>\n<td>CIN III</td>\n<td>Dysplastic cells in &gt;2/3 of the cervical epithelium</td>\n</tr>\n<tr>\n<td>Carcinoma in situ</td>\n<td>Carcinoma in situ</td>\n<td>Dysplastic cells in full-thickness of cervical epithelium but basement membrane is intact</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>\n<table>\n<tbody>\n<tr>\n<td><strong>LSIL</strong></td>\n<td><strong>HSIL</strong></td>\n</tr>\n<tr>\n<td>Atypia confined to the basal one-third of the epithelium</td>\n<td>Atypia involving upper two-third of the epithelium</td>\n</tr>\n<tr>\n<td>80% of LSILs are associated with high-risk HPVs, mostly HPV-16</td>\n<td>100% of HSILs are associated with high-risk HPVs, mostly HPV-16</td>\n</tr>\n<tr>\n<td>60% regress spontaneously; only 10% progress to HSIL.</td>\n<td>30% regress spontaneously; 10% progress to carcinoma</td>\n</tr>\n<tr>\n<td>Not a premalignant lesion</td>\n<td>Premalignant lesion</td>\n</tr>\n<tr>\n<td>Next step - Colposcopic directed biopsy</td>\n<td>Next step -&nbsp;Colposcopic directed biopsy + Endocervical curettage</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>Abbreviations:</p>\n<p>CIN: Cervical Intra-epithelial neoplasia</p>\n<p>LSIL: Low Squamous Intra-epithelial Lesion</p>\n<p>HSIL: High&nbsp;Squamous Intra-epithelial Lesion</p><hr><h3>Related Pearl: Management of CIN</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/1f5d51f1183f4d35857dd881e7f7f708x1280x1886.JPEG\" alt=\"Pearl Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1000",
      "difficulty": "easy"
    },
    {
      "text": "A 30-year-old sex worker presented with irregular menses, post-coital bleeding, and occasional foul-smelling vaginal discharge. She was advised to undergo a Pap smear. What is the best time for this investigation?",
      "choices": [
        {
          "id": 1,
          "text": "Immediately after menstruation"
        },
        {
          "id": 2,
          "text": "Around ovulation"
        },
        {
          "id": 3,
          "text": "Secretory phase"
        },
        {
          "id": 4,
          "text": "During menstruation"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The given case scenario is suggestive of <strong>cervical</strong>&nbsp;<strong>carcinoma</strong><strong>.</strong> The best time to do a Pap smear is <strong>around ovulation</strong>, but it can be performed at any other time as well.</p>\n<p>Prerequisites of doing a Pap smear:</p>\n<ul>\n<li>It should be done <strong>prior</strong> to <strong>vaginal examination</strong></li>\n<li>Lubricants should not be used</li>\n<li>The patient should not be menstruating during the pap test</li>\n<li>The ideal <strong>time</strong> is around <strong>ovulation</strong></li>\n<li>The patient should not have intercourse 24hrs prior to the test.</li>\n</ul>\n<p>Based on Pap smear findings, dysplasia of cervical cells is graded using various classification systems such as WHO grading, CIN grading, and the Bethesda system.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/89f54f6da4d54525afb281b593a33a63x600x2250.JPEG\" alt=\"Explanation Image\"><hr><h3>Related Pearl: Grades of cervical dysplasia</h3><p>A comparison of various naming systems based on cytology (Bethesda) and biopsy (CIN grade)</p>\n<table>\n<tbody>\n<tr>\n<td><strong>WHO grade</strong></td>\n<td><strong>Bethesda</strong></td>\n<td><strong>CIN grade</strong></td>\n<td><strong>Description</strong></td>\n</tr>\n<tr>\n<td>Mild Dysplasia</td>\n<td>LSIL</td>\n<td>CIN I</td>\n<td>Dysplastic cells in basal 1/3 of cervical epithelium</td>\n</tr>\n<tr>\n<td>Moderate Dysplasia</td>\n<td rowspan=\"3\">HSIL</td>\n<td>CIN II</td>\n<td>Dysplastic cells in basal 2/3 of cervical epithelium</td>\n</tr>\n<tr>\n<td>Severe dysplasia</td>\n<td>CIN III</td>\n<td>Dysplastic cells in &gt;2/3 of the cervical epithelium</td>\n</tr>\n<tr>\n<td>Carcinoma in situ</td>\n<td>Carcinoma in situ</td>\n<td>Dysplastic cells in full-thickness of cervical epithelium but basement membrane is intact</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>\n<table>\n<tbody>\n<tr>\n<td><strong>LSIL</strong></td>\n<td><strong>HSIL</strong></td>\n</tr>\n<tr>\n<td>Atypia confined to the basal one-third of the epithelium</td>\n<td>Atypia involving upper two-third of the epithelium</td>\n</tr>\n<tr>\n<td>80% of LSILs are associated with high-risk HPVs, mostly HPV-16</td>\n<td>100% of HSILs are associated with high-risk HPVs, mostly HPV-16</td>\n</tr>\n<tr>\n<td>60% regress spontaneously; only 10% progress to HSIL.</td>\n<td>30% regress spontaneously; 10% progress to carcinoma</td>\n</tr>\n<tr>\n<td>Not a premalignant lesion</td>\n<td>Premalignant lesion</td>\n</tr>\n<tr>\n<td>Next step - Colposcopic directed biopsy</td>\n<td>Next step -&nbsp;Colposcopic directed biopsy + Endocervical curettage</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>Abbreviations:</p>\n<p>CIN: Cervical Intra-epithelial neoplasia</p>\n<p>LSIL: Low Squamous Intra-epithelial Lesion</p>\n<p>HSIL: High&nbsp;Squamous Intra-epithelial Lesion</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0631",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is false about Schiller's test?",
      "choices": [
        {
          "id": 1,
          "text": "Lugol's iodine is used to paint the cervix"
        },
        {
          "id": 2,
          "text": "The epithelium is stained mahogany brown"
        },
        {
          "id": 3,
          "text": "Abnormal vaginal epithelium is stained"
        },
        {
          "id": 4,
          "text": "It detects the presence of glycogen in the epithelium"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The <strong>abnormal</strong> cells remain <strong>unstained</strong> on performing Schiller's test.</p>\n<p>Schiller's test, also known as VILI (visual inspection with Lugol's iodine), involves painting the cervix with <strong>Lugol's iodine. </strong>It is used to detect any abnormal cytology in the cervix and vagina, such as in cases of carcinoma cervix.&nbsp;</p>\n<p>The <strong>normal</strong> vaginal and cervical <strong>epithelium</strong> contains <strong>glycogen,</strong> therefore stains <strong>mahogany brown</strong> on being painted with Lugol's iodine. The<strong> abnormal cells</strong> remain <strong>unstained.</strong> These areas need to be <strong>biopsied</strong> and sent for histopathological examination.&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0628",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following would you not expect to see in the colposcopic biopsy of a patient with cervical intraepithelial neoplasia?",
      "choices": [
        {
          "id": 1,
          "text": "Dysplasia"
        },
        {
          "id": 2,
          "text": "Breach in basement membrane"
        },
        {
          "id": 3,
          "text": "Altered N:C ratio"
        },
        {
          "id": 4,
          "text": "Mitotic figures"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The <strong>basement membrane</strong> is<strong> intact</strong> in cervical intraepithelial neoplasia (CIN).</p>\n<p><strong>Features of CIN:</strong></p>\n<ul>\n<li>Varying degree of dysplasia</li>\n<li>Altered nuclear-cytoplasmic (N:C) ratio</li>\n<li>Hyperchromatic nuclei</li>\n<li>Mitotic figures</li>\n<li>Intact basement membrane.</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4981",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following methods is most commonly used for the treatment of CIN?",
      "choices": [
        {
          "id": 1,
          "text": "Cold-knife conization"
        },
        {
          "id": 2,
          "text": "Large loop excision of transformation zone"
        },
        {
          "id": 3,
          "text": "Electrocoagulation"
        },
        {
          "id": 4,
          "text": "Needle excision of transformation zone"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>Large loop excision of the transformation zone (<strong>LLETZ</strong>) is the most commonly used treatment option for cervical intraepithelial neoplasia (CIN). It is also known as loop electrosurgical excision procedure (<strong>LEEP</strong>).</p>\n<div class=\"page\" title=\"Page 506\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>It is applicable for the <strong>treatment of CIN</strong> anywhere in the lower genital tract. This uses electric current through a monopolar wire electrode to either cut or coagulate cervical lesions. Like other excisional procedures, it is done in the immediate post menstrual phase.</p>\n<p>The procedure involves&nbsp;<strong>minimal patient discomfort</strong>, cost, and complications. Since it can be performed using local anesthesia, it has become the primary outpatient treatment modality for high-grade cervical lesions.</p>\n</div>\n</div>\n</div><hr><h3>Related Pearl: Management of CIN</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/1f5d51f1183f4d35857dd881e7f7f708x1280x1886.JPEG\" alt=\"Pearl Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB5003",
      "difficulty": "easy"
    },
    {
      "text": "Which among the following is the treatment of choice when microinvasion of cervix neoplasia is suspected?",
      "choices": [
        {
          "id": 1,
          "text": "LLTEZ"
        },
        {
          "id": 2,
          "text": "LEEP"
        },
        {
          "id": 3,
          "text": "Conization"
        },
        {
          "id": 4,
          "text": "Hysterectomy"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Conization</strong> is the treatment of choice when microinvasion is suspected<strong>.</strong></p>\n<ul>\n<li>Indications of conization\n<ul>\n<li>Endocervical dysplasia</li>\n<li>Transformation zone is not completely visualized</li>\n<li>When there is discrepancy of findings between cytolology, colposcopy &amp; biopsy</li>\n<li>Microinvasion is suspected</li>\n</ul>\n</li>\n<li>Indications of hysterectomy\n<ul>\n<li>Older &amp; parous women</li>\n<li>Uterus is associated with fibroid, DUB, prolapsed</li>\n<li>Recurrence or persistent lesion</li>\n<li>In-situ adenocarcinoma cervix</li>\n</ul>\n</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB5008",
      "difficulty": "medium"
    },
    {
      "text": "A 40-year-old woman has cervical intraepithelial neoplasia III. What would be the management?",
      "choices": [
        {
          "id": 1,
          "text": "Hysterectomy"
        },
        {
          "id": 2,
          "text": "Trachelectomy"
        },
        {
          "id": 3,
          "text": "Conization"
        },
        {
          "id": 4,
          "text": "Colposcopy with LEEP"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Colposcopy with LEEP</strong> would be appropriate management for <strong>CIN III</strong>.</p>\n<p><strong>Loop electrosurgical excision procedure (LEEP)&nbsp;</strong>is an <strong>opd procedure</strong> done under <strong>colposcopic view</strong> and local anesthesia.Here, a low voltage current is passed through the loop and a cone of tissue is removed from the cervix. This procedure causes <strong>minimal bleeding</strong> and the tissue removed is sent for histopathological examination (HPE). This is the <strong>treatment of choice</strong> for <strong>CIN 2&amp;3</strong> of <strong>any age and parity</strong>.</p><hr><h3>Related Pearl: Management of CIN</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/1f5d51f1183f4d35857dd881e7f7f708x1280x1886.JPEG\" alt=\"Pearl Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7104",
      "difficulty": "medium"
    },
    {
      "text": "Which is the most common malignancy in women in India?",
      "choices": [
        {
          "id": 1,
          "text": "Cervical cancer"
        },
        {
          "id": 2,
          "text": "Breast cancer"
        },
        {
          "id": 3,
          "text": "Endometrial cancer"
        },
        {
          "id": 4,
          "text": "Ovarian cancer"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Breast cancer</strong> is the most common cancer in women in India as well as globally.&nbsp;<strong>Cervical cancer</strong> is the most common <strong>genital</strong> cancer in India.</p>\n<p>Lip and oral cavity cancer is the most common malignancy in men.</p>\n<p><strong>Risk factors</strong>&nbsp;for carcinoma cervix include:</p>\n<ul>\n<li>Human Papilloma virus (most important)</li>\n<li>Sexual intercourse before 18 years</li>\n<li>Multiple sexual partners</li>\n<li>Multiparity</li>\n<li>Poor personal hygiene</li>\n<li>Smoking and drug abuse</li>\n<li>Women with STD, HIV, HSV&nbsp;</li>\n<li>Immune suppression</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4975",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following is false regarding the transitional zone?",
      "choices": [
        {
          "id": 1,
          "text": "CIN originates from this site"
        },
        {
          "id": 2,
          "text": "It is a dynamic point"
        },
        {
          "id": 3,
          "text": "Nabothian cysts mark the original site"
        },
        {
          "id": 4,
          "text": "It is limited to external os"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The <strong>transitional zone</strong> or <strong>squamocolumnar junction</strong> is well outside the external os during the reproductive period. </p>\n<p>It is the site where the <strong>squamous</strong> epithelium lining the <strong>vagina</strong> merges with the <strong>columnar</strong> epithelium of the <strong>endocervix</strong>. The original squamocolumnar junction is marked by the presence of Nabothian cysts and glandular openings.</p>\n<p>It is a <strong>dynamic</strong> part and moves with age and hormonal influence:</p>\n<div class=\"page\" title=\"Page 19\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<ul>\n<li>During pregnancy and with oral contraceptives, it pouts out of os.</li>\n<li>Following menopause, it gets indrawn inside the os.</li>\n</ul>\n</div>\n</div>\n</div>\n<p>The <strong>cells</strong> here are <strong>highly sensitive</strong> to irritants, mutagens and viral agents such as HPV. Cancer screening using <strong>Pap smear</strong> involves scraping this area and studying the cells for nuclear changes.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0972",
      "difficulty": "easy"
    },
    {
      "text": "Identify the false statement regarding adenocarcinoma of the cervix.",
      "choices": [
        {
          "id": 1,
          "text": "Most common site is transformation zone"
        },
        {
          "id": 2,
          "text": "Cervical cancer is the second most common cancer among women in India"
        },
        {
          "id": 3,
          "text": "Most common in OCP users"
        },
        {
          "id": 4,
          "text": "Associated with HPV 18"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The most common site of adenocarcinoma is <strong>endocervix</strong>.</p>\n<p>It commonly occurs in young females and OCP users, and is associated with HPV 18.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0973",
      "difficulty": "medium"
    },
    {
      "text": "You would suspect and evaluate for carcinoma cervix in patients presenting with which of the following conditions?",
      "choices": [
        {
          "id": 1,
          "text": "Menorrhagia"
        },
        {
          "id": 2,
          "text": "Metrorrhagia"
        },
        {
          "id": 3,
          "text": "Polymenorrhea"
        },
        {
          "id": 4,
          "text": "Amenorrhea"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>Patients with carcinoma cervix most <strong>commonly</strong> present with <strong>metrorrhagia,</strong>&nbsp;now known as <strong>intermenstrual bleeding</strong>.</p>\n<p><strong>Post-coital bleeding</strong> is the most <strong>specific</strong> symptom of carcinoma cervix.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1027",
      "difficulty": "medium"
    },
    {
      "text": "What is the most common site of hematogenous metastasis of cervical cancer?",
      "choices": [
        {
          "id": 1,
          "text": "Lung"
        },
        {
          "id": 2,
          "text": "Liver"
        },
        {
          "id": 3,
          "text": "Bone"
        },
        {
          "id": 4,
          "text": "Bowel"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The most common site of <strong>hematogenous metastasis</strong> of cervical cancer is the&nbsp;<strong>lung.</strong></p>\n<p>About <strong>1-2%</strong> of patients with cervical carcinomas <strong>present</strong> with lung metastases, and 5-35% eventually develop lung metastases.&nbsp;</p>\n<p>Other common sites of blood-borne metastases include bone, liver and bowel.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1028",
      "difficulty": "easy"
    },
    {
      "text": "A 65-year-old woman comes for follow-up a few months after surgery for carcinoma cervix. On evaluation, she is found to have a recurrence of the malignancy. Which of the following is true about her condition?",
      "choices": [
        {
          "id": 1,
          "text": "Most common site of recurrence is pelvic lymph node"
        },
        {
          "id": 2,
          "text": "Mortality in patients with recurrence is due to pulmonary embolism"
        },
        {
          "id": 3,
          "text": "Treatment involves surgery with lymph node dissection"
        },
        {
          "id": 4,
          "text": "Recurrent tumor with largest diameter <3cm has good prognosis"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>A recurrent tumor with the largest diameter of <strong>&lt;3cm</strong> is associated with a&nbsp;<strong>good prognosis</strong>.&nbsp;</p>\n<p>The extent of recurrent disease and involvement of pelvic lymph nodes are prognostic factors for survival.&nbsp;An isolated central pelvic tumour with no involvement of the pelvic sidewall also has a good prognosis.&nbsp;</p>\n<p>Most <strong>recurrences</strong> are seen <strong>within 3 years</strong> and the prognosis is poor with <strong>uremia</strong> being the most common <strong>terminal event</strong>.&nbsp;Recurrences most <strong>commonly involve</strong> the <strong>pelvis </strong>than<strong>&nbsp;</strong>the para-aortic or pelvic lymph node.</p>\n<p>All patients with a suspected recurrence should undergo <strong>PET/CT</strong> for <strong>evaluation</strong> and <strong>biopsy</strong> for <strong>confirmation</strong>.</p>\n<p>Treatment involves either <strong>radical chemoradiation or pelvic exenteration</strong>. Concurrent chemotherapy with cisplatin and/or 5-fluorouracil&nbsp;may improve the outcome.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1030",
      "difficulty": "hard"
    },
    {
      "text": "Identify the true statement about the staging of cancer cervix.",
      "choices": [
        {
          "id": 1,
          "text": "Clinical examination is the first step in staging"
        },
        {
          "id": 2,
          "text": "Tumor markers are important for diagnosis of metastasis"
        },
        {
          "id": 3,
          "text": "CT scan is the best method to assess principal tumors"
        },
        {
          "id": 4,
          "text": "MRI is the best method to assess nodal metastasis"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Clinical examination</strong> is the<strong> first</strong> <strong>step</strong> in staging carcinoma cervix.</p>\n<p>Clinical examination was the principal method in staging until the 2018 FIGO guidelines which recommended the use of&nbsp;<strong>imaging and histological investigations </strong>when available. USG, CT, MRI, and PET-CT can be used to assess the extent of the tumor, nodal status, and local or systemic spread.</p>\n<p><strong>MRI</strong> is the best method to assess the <strong>principal tumor</strong>&nbsp;while <strong>PET-CT</strong> is the best method to assess <strong>nodal metastasis.</strong></p>\n<p>FIGO no longer mandates biochemical investigations, such as tumor markers, for diagnosis of metastasis.</p><hr><h3>Related Pearl: Staging of Carcinoma Cervix</h3><p><strong>Stage I - limited to the cervix</strong></p>\n<ul>\n<li>A: Microscopic lesion\n<ul>\n<li>A1 - stromal invasion &lt;3mm depth</li>\n<li>A2 - a stromal invasion of &ge;3 and &lt;5mm depth</li>\n</ul>\n</li>\n<li>B: Macroscopic lesion\n<ul>\n<li>B1 - stromal invasion &ge;5mm depth &amp; tumor size &lt;2cm&nbsp;</li>\n<li>B2 - tumor size &ge;2cm to &lt;4cm&nbsp;</li>\n<li>B3 - tumor size &ge;4cm&nbsp;</li>\n</ul>\n</li>\n</ul>\n<p><strong>Stage II - involves upper 2/3 of vagina</strong></p>\n<ul>\n<li>A: Extends to the upper two-thirds of the vagina without parametrial involvement\n<ul>\n<li>A1 - tumor size &lt;4cm&nbsp;</li>\n<li>A2 - tumor size &ge;4cm&nbsp;</li>\n</ul>\n</li>\n<li>B: Extends to parametrium but not upto the pelvic wall.</li>\n</ul>\n<p><strong>Stage III - spreads to lower 1/3 of vagina</strong></p>\n<ul>\n<li>A: Extends to lower 1/3 of the vagina</li>\n<li>B: Extends to the pelvic wall (hydronephrosis/non-functioning kidney)</li>\n<li>C: Involvement of the pelvic and/or para-aortic lymph nodes, irrespective of the tumor size and extent\n<ul>\n<li>C1: pelvic lymph node involved</li>\n<li>C2: para-aortic lymph node&nbsp;involved</li>\n</ul>\n</li>\n</ul>\n<p><strong>Stage IV - metastasis</strong></p>\n<ul>\n<li>A: Bladder/bowel involvement (adjacent pelvic organs)</li>\n<li>B: Distant metastasis</li>\n</ul>\n<p>Note:&nbsp;The involvement of vascular/lymphatic spaces does not change the staging. The lateral extent of the lesion is no longer considered.</p>\n<p>Stage IIIB is the most common stage of presentation.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4989",
      "difficulty": "medium"
    },
    {
      "text": "The CT of a patient with cervical carcinoma revealed a lesion of 6 cm, extending to the upper part of the vagina and parametrium. What is the stage of the disease?",
      "choices": [
        {
          "id": 1,
          "text": "Stage II A"
        },
        {
          "id": 2,
          "text": "Stage II B"
        },
        {
          "id": 3,
          "text": "Stage III A"
        },
        {
          "id": 4,
          "text": "Stage III B"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The stage of cervical carcinoma is <strong>II&nbsp;B</strong> as it involves the&nbsp;<strong>upper</strong> part of the <strong>vagina</strong> and <strong>parametrium.</strong></p><hr><h3>Related Pearl: Staging of Carcinoma Cervix</h3><p><strong>Stage I - limited to the cervix</strong></p>\n<ul>\n<li>A: Microscopic lesion\n<ul>\n<li>A1 - stromal invasion &lt;3mm depth</li>\n<li>A2 - a stromal invasion of &ge;3 and &lt;5mm depth</li>\n</ul>\n</li>\n<li>B: Macroscopic lesion\n<ul>\n<li>B1 - stromal invasion &ge;5mm depth &amp; tumor size &lt;2cm&nbsp;</li>\n<li>B2 - tumor size &ge;2cm to &lt;4cm&nbsp;</li>\n<li>B3 - tumor size &ge;4cm&nbsp;</li>\n</ul>\n</li>\n</ul>\n<p><strong>Stage II - involves upper 2/3 of vagina</strong></p>\n<ul>\n<li>A: Extends to the upper two-thirds of the vagina without parametrial involvement\n<ul>\n<li>A1 - tumor size &lt;4cm&nbsp;</li>\n<li>A2 - tumor size &ge;4cm&nbsp;</li>\n</ul>\n</li>\n<li>B: Extends to parametrium but not upto the pelvic wall.</li>\n</ul>\n<p><strong>Stage III - spreads to lower 1/3 of vagina</strong></p>\n<ul>\n<li>A: Extends to lower 1/3 of the vagina</li>\n<li>B: Extends to the pelvic wall (hydronephrosis/non-functioning kidney)</li>\n<li>C: Involvement of the pelvic and/or para-aortic lymph nodes, irrespective of the tumor size and extent\n<ul>\n<li>C1: pelvic lymph node involved</li>\n<li>C2: para-aortic lymph node&nbsp;involved</li>\n</ul>\n</li>\n</ul>\n<p><strong>Stage IV - metastasis</strong></p>\n<ul>\n<li>A: Bladder/bowel involvement (adjacent pelvic organs)</li>\n<li>B: Distant metastasis</li>\n</ul>\n<p>Note:&nbsp;The involvement of vascular/lymphatic spaces does not change the staging. The lateral extent of the lesion is no longer considered.</p>\n<p>Stage IIIB is the most common stage of presentation.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB5001",
      "difficulty": "medium"
    },
    {
      "text": "A 50-year-old woman presented to her gynecologist with postcoital bleeding. She was diagnosed with carcinoma cervix stage IB after evaluation. What is the treatment of choice for this patient?",
      "choices": [
        {
          "id": 1,
          "text": "Type I  hysterectomy"
        },
        {
          "id": 2,
          "text": "Type II hysterectomy"
        },
        {
          "id": 3,
          "text": "Type III hysterectomy"
        },
        {
          "id": 4,
          "text": "Type IV hysterectomy"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Type III hysterectomy</strong>&nbsp;is the treatment of choice in carcinoma cervix - <strong>stage IB</strong>. It involves radical hysterectomy with pelvic lymphadenectomy and para-aortic lymph node evaluation.</p>\n<div class=\"page\" title=\"Page 697\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Stage IB is defined as a macroscopic lesion still confined to the cervix, with the depth of invasion &ge;5mm. It is the first stage in which lesions become clinically visible.</p>\n<p>Hysterectomy types include:</p>\n<ul>\n<li>Type I - Simple / extrafascial</li>\n<li>Type II - Modified radical / Wertheim</li>\n<li>Type III - Radical / Meigs-Wertheim</li>\n<li>Type IV - Extended radical Hysterectomy</li>\n<li>Type V - Exenteration.</li>\n</ul>\n</div>\n</div>\n</div>\n</div><hr><h3>Related Pearl: General treatment for primary invasive cervical carcinoma</h3><table>\n<tbody>\n<tr>\n<td><strong>Stages</strong></td>\n<td><strong>Fertility preserved</strong></td>\n<td><strong>Fertility not preserved</strong></td>\n</tr>\n<tr>\n<td>IA1</td>\n<td>Cervical conization</td>\n<td>Simple hysterectomy</td>\n</tr>\n<tr>\n<td>IA1 (LVSI)</td>\n<td>Radical trachelectomy and pelvic lymphadenectomy</td>\n<td>Modified radical hysterectomy and pelvic lymphadenectomy</td>\n</tr>\n<tr>\n<td>IA2</td>\n<td>\n<p>1. Cervical conization with extraperitoneal pelvic lymphadenectomy</p>\n<p>2. Radical trachelectomy and pelvic lymphadenectomy</p>\n</td>\n<td>Modified Radical hysterectomy and pelvic lymphadenectomy</td>\n</tr>\n<tr>\n<td>\n<p>IB1</p>\n<p>Some IB2, IIA1</p>\n</td>\n<td>Radical trachelectomy and pelvic lymphadenectomy (or)chemoradiation</td>\n<td>Radical hysterectomy and pelvic lymphadenectomy (or) chemoradiation</td>\n</tr>\n<tr>\n<td>Bulky IB3, IIA2</td>\n<td colspan=\"2\">Chemoradiation</td>\n</tr>\n<tr>\n<td>IIB to IVA</td>\n<td colspan=\"2\">Chemoradiation or pelvic exenteration&nbsp;</td>\n</tr>\n<tr>\n<td>IVB</td>\n<td colspan=\"2\">Palliative chemotherapy or palliative radiotherapy or supportive care</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p><hr><h3>Related Pearl: Staging of Carcinoma Cervix</h3><p><strong>Stage I - limited to the cervix</strong></p>\n<ul>\n<li>A: Microscopic lesion\n<ul>\n<li>A1 - stromal invasion &lt;3mm depth</li>\n<li>A2 - a stromal invasion of &ge;3 and &lt;5mm depth</li>\n</ul>\n</li>\n<li>B: Macroscopic lesion\n<ul>\n<li>B1 - stromal invasion &ge;5mm depth &amp; tumor size &lt;2cm&nbsp;</li>\n<li>B2 - tumor size &ge;2cm to &lt;4cm&nbsp;</li>\n<li>B3 - tumor size &ge;4cm&nbsp;</li>\n</ul>\n</li>\n</ul>\n<p><strong>Stage II - involves upper 2/3 of vagina</strong></p>\n<ul>\n<li>A: Extends to the upper two-thirds of the vagina without parametrial involvement\n<ul>\n<li>A1 - tumor size &lt;4cm&nbsp;</li>\n<li>A2 - tumor size &ge;4cm&nbsp;</li>\n</ul>\n</li>\n<li>B: Extends to parametrium but not upto the pelvic wall.</li>\n</ul>\n<p><strong>Stage III - spreads to lower 1/3 of vagina</strong></p>\n<ul>\n<li>A: Extends to lower 1/3 of the vagina</li>\n<li>B: Extends to the pelvic wall (hydronephrosis/non-functioning kidney)</li>\n<li>C: Involvement of the pelvic and/or para-aortic lymph nodes, irrespective of the tumor size and extent\n<ul>\n<li>C1: pelvic lymph node involved</li>\n<li>C2: para-aortic lymph node&nbsp;involved</li>\n</ul>\n</li>\n</ul>\n<p><strong>Stage IV - metastasis</strong></p>\n<ul>\n<li>A: Bladder/bowel involvement (adjacent pelvic organs)</li>\n<li>B: Distant metastasis</li>\n</ul>\n<p>Note:&nbsp;The involvement of vascular/lymphatic spaces does not change the staging. The lateral extent of the lesion is no longer considered.</p>\n<p>Stage IIIB is the most common stage of presentation.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB5013",
      "difficulty": "hard"
    },
    {
      "text": "A 30-year-old woman is found to have a lesion in the cervix which is 7mm wide and has a depth of 4mm. She has one child and wishes to preserve fertility. What is the most appropriate management?",
      "choices": [
        {
          "id": 1,
          "text": "Cryoablation"
        },
        {
          "id": 2,
          "text": "Cone biopsy"
        },
        {
          "id": 3,
          "text": "Radical trachelectomy with pelvic lymphadenectomy"
        },
        {
          "id": 4,
          "text": "LEEP"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The woman has <strong>stage I A2</strong> cervical cancer and the most appropriate management is <strong>radical trachelectomy&nbsp;with pelvic lymphadenectomy.</strong></p>\n<p>Radical trachelectomy&nbsp;is a fertility-preserving surgical procedure. This involves the&nbsp;removal of the entire cervix and parametrium.</p>\n<p><strong>Cervical conization&nbsp;</strong>with laparoscopic or extraperitoneal <strong>pelvic lymphadenectomy</strong> is an alternative that also preserves fertility.</p><hr><h3>Related Pearl: General treatment for primary invasive cervical carcinoma</h3><table>\n<tbody>\n<tr>\n<td><strong>Stages</strong></td>\n<td><strong>Fertility preserved</strong></td>\n<td><strong>Fertility not preserved</strong></td>\n</tr>\n<tr>\n<td>IA1</td>\n<td>Cervical conization</td>\n<td>Simple hysterectomy</td>\n</tr>\n<tr>\n<td>IA1 (LVSI)</td>\n<td>Radical trachelectomy and pelvic lymphadenectomy</td>\n<td>Modified radical hysterectomy and pelvic lymphadenectomy</td>\n</tr>\n<tr>\n<td>IA2</td>\n<td>\n<p>1. Cervical conization with extraperitoneal pelvic lymphadenectomy</p>\n<p>2. Radical trachelectomy and pelvic lymphadenectomy</p>\n</td>\n<td>Modified Radical hysterectomy and pelvic lymphadenectomy</td>\n</tr>\n<tr>\n<td>\n<p>IB1</p>\n<p>Some IB2, IIA1</p>\n</td>\n<td>Radical trachelectomy and pelvic lymphadenectomy (or)chemoradiation</td>\n<td>Radical hysterectomy and pelvic lymphadenectomy (or) chemoradiation</td>\n</tr>\n<tr>\n<td>Bulky IB3, IIA2</td>\n<td colspan=\"2\">Chemoradiation</td>\n</tr>\n<tr>\n<td>IIB to IVA</td>\n<td colspan=\"2\">Chemoradiation or pelvic exenteration&nbsp;</td>\n</tr>\n<tr>\n<td>IVB</td>\n<td colspan=\"2\">Palliative chemotherapy or palliative radiotherapy or supportive care</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p><hr><h3>Related Pearl: Staging of Carcinoma Cervix</h3><p><strong>Stage I - limited to the cervix</strong></p>\n<ul>\n<li>A: Microscopic lesion\n<ul>\n<li>A1 - stromal invasion &lt;3mm depth</li>\n<li>A2 - a stromal invasion of &ge;3 and &lt;5mm depth</li>\n</ul>\n</li>\n<li>B: Macroscopic lesion\n<ul>\n<li>B1 - stromal invasion &ge;5mm depth &amp; tumor size &lt;2cm&nbsp;</li>\n<li>B2 - tumor size &ge;2cm to &lt;4cm&nbsp;</li>\n<li>B3 - tumor size &ge;4cm&nbsp;</li>\n</ul>\n</li>\n</ul>\n<p><strong>Stage II - involves upper 2/3 of vagina</strong></p>\n<ul>\n<li>A: Extends to the upper two-thirds of the vagina without parametrial involvement\n<ul>\n<li>A1 - tumor size &lt;4cm&nbsp;</li>\n<li>A2 - tumor size &ge;4cm&nbsp;</li>\n</ul>\n</li>\n<li>B: Extends to parametrium but not upto the pelvic wall.</li>\n</ul>\n<p><strong>Stage III - spreads to lower 1/3 of vagina</strong></p>\n<ul>\n<li>A: Extends to lower 1/3 of the vagina</li>\n<li>B: Extends to the pelvic wall (hydronephrosis/non-functioning kidney)</li>\n<li>C: Involvement of the pelvic and/or para-aortic lymph nodes, irrespective of the tumor size and extent\n<ul>\n<li>C1: pelvic lymph node involved</li>\n<li>C2: para-aortic lymph node&nbsp;involved</li>\n</ul>\n</li>\n</ul>\n<p><strong>Stage IV - metastasis</strong></p>\n<ul>\n<li>A: Bladder/bowel involvement (adjacent pelvic organs)</li>\n<li>B: Distant metastasis</li>\n</ul>\n<p>Note:&nbsp;The involvement of vascular/lymphatic spaces does not change the staging. The lateral extent of the lesion is no longer considered.</p>\n<p>Stage IIIB is the most common stage of presentation.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1038",
      "difficulty": "medium"
    },
    {
      "text": "Which among the following are contraindications for radiotherapy in carcinoma cervix?<div class='question-desc-html'><ol>\n<li>Pelvic inflammatory disease</li>\n<li>Vaginal stenosis</li>\n<li>Post-menopausal status</li>\n<li>Adenocarcinoma</li>\n<li>Associated prolapse</li>\n</ol></div>",
      "choices": [
        {
          "id": 1,
          "text": "1, 2, 3"
        },
        {
          "id": 2,
          "text": "2, 4, 5"
        },
        {
          "id": 3,
          "text": "1, 2, 3, 5"
        },
        {
          "id": 4,
          "text": "1, 2, 4, 5"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Post-menopausal status is not a contraindication&nbsp;for radiotherapy in carcinoma cervix.</p>\n<p><strong>Contraindications</strong> for <strong>radiotherapy in carcinoma cervix</strong> include:</p>\n<ul>\n<li>Pelvic inflammatory disease</li>\n<li>Young patient (to preserve ovarian function)</li>\n<li>Associated myoma, prolapse, ovarian tumor, genital fistula</li>\n<li>Vaginal stenosis</li>\n<li>Adenocarcinoma or adenosquamous carcinoma &ndash; surgery preferred.</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB5021",
      "difficulty": "medium"
    },
    {
      "text": "You are planning to administer radiotherapy to a 58-year-old woman diagnosed with carcinoma cervix. What is the dose to be administered at point B?",
      "choices": [
        {
          "id": 1,
          "text": "7000 cGY"
        },
        {
          "id": 2,
          "text": "6000 cGY"
        },
        {
          "id": 3,
          "text": "5000 cGy"
        },
        {
          "id": 4,
          "text": "8000 cGy"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>In the treatment of carcinoma cervix, the dose to be administered at point B is&nbsp;<strong>6000 cGy</strong>.</p>\n<p>Radiotherapy in carcinoma cervix:</p>\n<table>\n<tbody>\n<tr>\n<td>&nbsp;</td>\n<td><strong>Point A</strong></td>\n<td><strong>Point B</strong></td>\n</tr>\n<tr>\n<td><strong>Location</strong></td>\n<td>2cm above and 2cm lateral to external os</td>\n<td>2cm above and 5cm lateral to external os</td>\n</tr>\n<tr>\n<td><strong>Structure</strong></td>\n<td>Paracervical/Parametrial lymph node</td>\n<td>Obturator lymph node</td>\n</tr>\n<tr>\n<td><strong>Dose</strong></td>\n<td>7000-8000 cGy</td>\n<td>6000 cGy</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/e3ce586ef69f426cac36b26d45f3259ex1280x1211.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1031",
      "difficulty": "medium"
    }
  ]
}